Content area

|
|

Tendenser inden for onkologiske fase 1-forsøg

Forfatter(e)
Kristoffer Staal Rohrberg, Camilla Qvortrup, Martin Højgaard & Iben Spanggaard
Fase 1 Enheden, Onkologisk Klinik, Rigshospitalet

Ugeskr Læger 2019;181:V05190301
Reference: 
Ugeskr Læger 2019;181:V05190301
Blad nummer: 

Kristoffer Staal Rohrberg, Camilla Qvortrup, Martin Højgaard & Iben Spanggaard:

Trends in oncological phase I trials

Ugeskr Læger 2019;181:V05190301

This review summarises the current knowledge of anticancer therapy. More than 1,100 cancer drugs are currently under development in the United States. The increasing biological insight and platforms for high throughput screening of drugs have changed the developmental landscape of anticancer therapies from classical cytotoxic agents to targeted agents and immunotherapy. There is an increasing number of targeted agents, which are only efficacious in tumours harbouring specific genomic alterations in early clinical development. Furthermore, the landscape of immunotherapy broadens, and personalised immunotherapy is in development. The integration of genomic testing into early clinical oncology trials is increasing.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Hanne Pedersen | 17/11
1 Kommentar
af Mads Aage Toft Kristensen | 16/11
1 Kommentar
af Ketil Bjerregård | 15/11
1 Kommentar
af Jens Lund Ahrenkiel | 15/11
1 Kommentar
af Nicolaj Markus Stilling | 15/11
2 kommentarer
af Marianne Puge Nielsen | 13/11
1 Kommentar
af Akil Raad Kami Abdel-Wahab Walli | 13/11
6 kommentarer
af Larry Højgaard Kristiansen | 11/11
1 Kommentar